PPARγ ligands glitazones (rosiglitazone and pioglitazone, Figure 1) are deemed as insulin sensitizer to improve the symptoms of patients with Type 2 diabetes mellitus (T2DM) [9]. This evidence concerns the gene INS and type 2 diabetes mellitus.